Recent advances in self-expanding stents for use in the superficial femoral and popliteal arteries

References

• Fowkes F, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382(9901):1329-40
   PubMed Web of Science ®Google Scholar
• Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3):510-15
   PubMed Web of Science ®Google Scholar
• Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013;61(16):1736-43
   PubMed Web of Science ®Google Scholar
• Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013;309(5):453-60
   PubMed Web of Science ®Google Scholar
• Westin GG, Armstrong EJ, Bang H, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014;63(7):682-90
   PubMed Web of Science ®Google Scholar
• Bosiers M, Deloose K, Callaert J, et al. Refining stent technologies for femoral interventions. J Cardiovasc Surg (Torino) 2012;53(4):465-73
   PubMedGoogle Scholar
• Vardi M, Novack V, Pencina MJ, et al. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Self-expanding peripheral stent. Available from: www.accessdata.fda.gov/cdrh_docs/pdf/P000033b.pdf
   Google Scholar
• Jahnke T, Voshage G, Müller-Hülsbeck S, et al. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002;13(3):257-66
   PubMedGoogle Scholar
• Ansel GM, Botti CF, George BS, Kazienko BT. Clinical results for the training-phase roll-in patients in the Intracoil femoralpopliteal stent trial. Cathet Cardiovasc Intervent 2002;56(4):443-9
   PubMedGoogle Scholar
• Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354(18):1879-88
   PubMed Web of Science ®Google Scholar
• Schillinger M, Sabeti S, Dick P, et al. Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting. Circulation 2007;115(21):2745-9
   PubMed Web of Science ®Google Scholar
• Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 2007;116(3):285-92
   PubMedGoogle Scholar
• Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009;74(7):1090-5
   PubMedGoogle Scholar
• Chalmers N, Walker PT, Belli A-M, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol 2012;36(2):353-61
   PubMedGoogle Scholar
• Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3(3):267-76
   PubMed Web of Science ®Google Scholar
• Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012;19(1):1-9
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Saeed H, Alvandi B, et al. Nitinol Self-Expanding Stents vs. Balloon Angioplasty for Very Long Femoropopliteal Lesions. J Endovasc Ther 2014;21(1):34-43
   PubMed Web of Science ®Google Scholar
• Bosiers M, Torsello G, Gissler H, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009;16(3):261-9
   PubMed Web of Science ®Google Scholar
• Matsumura JS, Yamanouchi D, Goldstein JA, et al. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Super. J Vasc Surg 2013;58(1):73-83
   PubMedGoogle Scholar
• Three-year clinical follow-up presented for the DURABILITY II study. Available from: http://evtoday.com/2013/09/three-year-clinical-follow-up-presented-for-the-durability-ii-study
   Google Scholar
• Peripheral stent system. Available from: www.abbottvascular.com/static/cms_workspace/pdf/ifu/peripheral_intervention/eIFU_Supera.pdf
   Google Scholar
• Scheinert D, Grummt L, Piorkowski M, et al. A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther 2011;18(6):745-52
   PubMed Web of Science ®Google Scholar
• Werner M, Paetzold A, Banning-Eichenseer U, et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention 2014. [Epub ahead of print]
   Google Scholar
• Chan YC, Cheng SW, Ting AC, Cheung GC. Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents. J Vasc Surg 2014;59(2):384-91
   PubMedGoogle Scholar
• Scheinert D, Werner M, Scheinert S, et al. Treatment of Complex Atherosclerotic Popliteal Artery Disease With a New Self-Expanding Interwoven Nitinol Stent. JACC Cardiovasc Interv 2013;6(1):65-71
   PubMed Web of Science ®Google Scholar
• Werner M, Piorkowski M, Thieme M, et al. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment. J Endovasc Ther 2013;20(6):759-66
   PubMed Web of Science ®Google Scholar
• Jaff MR. SMART nitinol self-expanding stent in the treatment of obstructive superficial femoral artery disease: Three-year clinical outcomes from the STROLL trial. Presented at: international Symposium on Endovascular Therapy; 21 January 2014; Miami Beach, FL, USA
   Google Scholar
• aird JR, Jain A, Zeller T, et al. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther 2014;21(2):202-12
   PubMedGoogle Scholar
• Schulte K, Müller-Hülsbeck S, Cao P, et al. MISAGO 1: first-in-man clinical trial with Misago nitinol stent. EuroIntervention 2010;5(6):687-91
   PubMedGoogle Scholar
• Schulte K, Kralj I, Gissler H, et al. MISAGO 2: one-Year outcomes after implantation of the misago self-expanding nitinol stent in the superficial femoral and popliteal arteries of 744 patients. J Endovasc Ther 2012;19(6):774-84
   PubMedGoogle Scholar
• Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106(12):1505-9
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16(3):331-8
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13(6):701-10
   PubMed Web of Science ®Google Scholar
• Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54(2):394-401
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month zilver ptx randomized study results. Circ Cardiovasc Interv 2011;4(5):495-504
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61(24):2417-27
   PubMed Web of Science ®Google Scholar
• Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18(5):613-23
   PubMed Web of Science ®Google Scholar
• Bosiers MM, Peeters PP, Tessarek JJ, et al. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino) 2013;54(1):115-22
   PubMed Web of Science ®Google Scholar
• Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013;6(3):274-81
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of femoropopliteal in-stent restenosis: Association with long-term outcomes after endovascular intervention. Catheter Cardiovasc Interv 2013;82(7):1168-74
   PubMed Web of Science ®Google Scholar
• McQuade K, Gable D, Pearl G, et al. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg 2010;52(3):584-90
   PubMedGoogle Scholar
• Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg 2013;58(2):386-95
   PubMed Web of Science ®Google Scholar
• Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol 2013;24(2):165-73
   PubMed Web of Science ®Google Scholar
• Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare metal stents for complex femoro-popliteal artery lesions: the randomized VIASTAR trial. J Am Coll Cardiol 2013;62(15):1320-7
   PubMedGoogle Scholar
• Johnston PC, Vartanian SM, Runge SJ, et al. Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease. J Vasc Surg 2012;56(4):998-7
   PubMedGoogle Scholar
• Katsanos K, Spiliopoulos S, Karunanithy N, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg 2014;59(4):1123-33
   PubMed Web of Science ®Google Scholar
• Werner M, Micari A, Cioppa A, et al. Evaluation of the biodegradable peripheral igaki-tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA Study. JACC Cardiovasc Interv 2014;7(3):305-12
   PubMed Web of Science ®Google Scholar
• Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7(1):10-19
   PubMed Web of Science ®Google Scholar
• Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118(13):1358-65
   PubMed Web of Science ®Google Scholar